
    
      Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing
      recurrence after surgery at least in 20-50% after 5 years of follow-up. The long acting GnRH
      antagonist degarelix, which do not have the flare-up effect at the opposite of GnRH agonist
      and strongly suppress LH secretion and thecal cell activity may show a better effects on
      endometrial implants than GnRH agonist.
    
  